INVOcell Fertility Treatment Now Offered at the Center for Reproductive Health at Tri-Star Centennial Medical Center in Nashville
NASHVILLE, TN and MEDFORD, MA / August 3, 2017 / INVO Bioscience, Inc. (OTC PINK: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, and Center for Reproductive Health (“CRH”) at Tri-Star Centennial Medical Center in Nashville, Tennessee, are now offering the INVOcell device and procedure to its patients. Since 1995, CRH has been an innovator in infertility treatment, and now genetics care, and have helped thousands of patients worldwide realize their dreams of starting a family.
INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman’s body, in vivo. The INVO Solution allows women to incubate their own gametes, providing a psychological benefit, while reducing the risk of wrong embryo transfer. Utilizing a mild stimulation protocol, it decreases the number of oocytes required, which may reduce the risk of severe ovarian hyperstimulation (OHSS), reduce the risk of multiple births, and/or reduce the need for embryo cryopreservation and storage. As a lower cost option to traditional IVF, INVOcell expands access to patients who may be unable to or otherwise cannot afford the traditional method, or who would prefer a more natural, cultural, or religious-appropriate choice.
Dr. Jaime Vasquez, medical director at the Center for Reproductive Health at Tri-Star Centennial Medical Center, commented, “We’ve seen many patients who would like to undergo in-vitro fertilization (IVF), but the time and financial requirements of the procedure can be prohibitive. With the development of the new INVOcell device, we are able to greatly reduce the cost of treatment by minimizing all lab costs. We are excited to now offer treatment with the INVOcell device at our Nashville fertility clinic.”
Well known in his field, Dr. Vasquez has previously held faculty positions at Vanderbilt, Thomas Jefferson University in Philadelphia and the University of Wisconsin Hospital in Madison. He has been invited to lecture at scientific and medical meetings throughout the world and has played a key investigative role in numerous research projects in his field. He has also published in multiple peer review journals both nationally and internationally and has co-authored multiple textbooks.
“I am pleased that Dr. Vasquez and his team at Center for Reproductive Health at Tri-Star Centennial Medical Center have become early adopters of the INVOcell solution,” said Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience. “As one of the leading fertility centers in Middle Tennessee, we believe the INVOcell, which exhibits comparable pregnancy rates to traditional IVF at half the price, will allow for increased access to treatment for patients who otherwise couldn’t afford it. While most of the talk in the country today has been on the rising cost of healthcare, we are pleased to be bucking this trend by introducing a solution that helps drive down the cost in a meaningful way without sacrificing efficacy.”
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
INVO Bioscience, Inc.
Kathleen Karloff, CEO
978-878-9505 ext. 504
Center for Reproductive Health at Tri-Star Centennial Medical Center
Dr. Jaime Vasquez, Medical Director